Oral Bacteria and Cancer

In 1994, the World Health Organization did something it had never done before. It declared a bacterium a definite cause of cancer in humans. The species was Helicobacter pylori, the cancer was gastric, and the designation landed like a rupture in a field that had considered its list of carcinogens essentially closed. Age, heredity, diet, tobacco, and viruses — those were the culprits. Bacteria were an infection problem, not a cancer problem. And then, suddenly, they were both. That institutional moment is where Whitmore and Lamont begin their review of oral bacteria and cancer, treating it not as a historical footnote but as a permission slip. If H. pylori could cross from infection into oncology, what else had been dismissed too quickly? The answer, it turns out, may have been living in your mouth the whole time. The oral cavity is not a random collection of germs. It is a complex, multispecies ecosystem that normally exists in a balanced immunoinflammatory relationship with its human host. Many different bacterial species coexist, held in check by host defenses and by the dynamics of the community itself. Whitmore and Lamont describe this as a steady state — and like most steady states in biology, the interesting things happen when it breaks down. The breakdown has a name: dysbiosis. It means the balance tips, and the community changes character. One species alters the environment or the host's immune response in a way that favors a very different microbial mix. According to Whitmore and Lamont, Porphyromonas gingivalis is the instigator — it disrupts the normal equilibrium and shifts the community toward a disease-prone state. Once P. gingivalis has done that, other community members can flourish as opportunistic followers. The most important of these is Fusobacterium nucleatum. It becomes, in the authors' framing, opportunistically pathogenic. The combined effect of this dysbiotic microbial community together with a dysregulated immune response produces periodontal disease. Not one rogue bacterium acting alone, but a community that has tipped into a new configuration. These two well-studied periodontal organisms — P. gingivalis and F. nucleatum — are now the focal point for the association between oral bacteria and cancer. The epidemiological case for that association is built on a striking observation: these bacteria keep showing up where they shouldn't. The most direct link is with oral squamous cell carcinoma, one of the most common cancers worldwide. Multiple studies report that oral squamous cell carcinoma surfaces harbor significantly higher levels of Porphyromonas and Fusobacterium compared with contiguous healthy mucosa from the same patient. Immunohistochemistry using P. gingivalis antibodies detected both higher frequency and greater intensity of staining in gingival carcinomas versus healthy gingival tissue. These bacteria aren't just in the neighborhood — they are in the tumor itself. The pattern extends well beyond the mouth. In a prospective cohort study of over four hundred cases and controls, individuals with high antibody levels to P. gingivalis had a roughly two-fold increase in pancreatic cancer risk after adjustment for known risk factors. In the large National Health and Nutrition Examination Survey III, orodigestive cancer mortality was associated with P. gingivalis antibody levels independently of periodontal disease itself. F. nucleatum tells a parallel story in colorectal cancer — multiple studies identified it as one of the more abundant species in and around colorectal tumors, and its levels correlated with lymph node metastases. The same organisms, at the scene of the crime, across multiple cancer types. Whitmore and Lamont are careful to frame this as associative evidence. But they also point out that across oral squamous cell carcinoma, pancreatic cancer, and colorectal cancer, the spatial and temporal pattern is hard to dismiss. Now comes the harder question: could these bacteria actually be causing cancer, or are they just colonizing tissue that is already compromised? This is where Whitmore and Lamont turn to mechanisms, and the molecular detail is where the argument gets genuinely compelling. Start with P. gingivalis. One of its most striking properties is its ability to suppress apoptosis — programmed cell death, the body's primary mechanism for disposing of damaged or abnormal cells. In primary gingival epithelial cells, P. gingivalis activates a signaling cascade through Jak1, Akt, and Stat3 that targets the mitochondrial apoptosis pathway. It tips the ratio of anti-apoptotic to pro-apoptotic proteins — specifically raising Bcl2 relative to Bax — and blocks the downstream release of cytochrome c, preventing activation of the executioner enzyme caspase-3. The bacterium also up-regulates a microRNA called miR-203, which suppresses a negative regulator called SOCS3 and further inhibits apoptosis. And it secretes an enzyme, nucleoside diphosphate kinase, that functions as an ATPase to cleave extracellular ATP, preventing a separate ATP-dependent apoptosis pathway from triggering through the purinergic receptor P2X7. That same ATP-clearing activity also reduces activation of the NLRP3 inflammasome on dendritic cells, blunting secretion of interleukin-1 beta — a cytokine that Whitmore and Lamont note is important for priming the tumor-killing CD8-positive T cells that the immune system relies on to find and destroy abnormal cells. So P. gingivalis is doing two things simultaneously: keeping potentially damaged epithelial cells alive, and weakening the immune surveillance that would otherwise destroy them. The bacterium goes further. It accelerates cell-cycle progression through S phase by manipulating cyclin and cyclin-dependent kinase activity and by reducing levels of the p53 tumor suppressor protein — and this effect depends on the bacterial FimA adhesin, because it disappears in fimbrial-deficient mutants. On invasion, P. gingivalis produces gingipain cysteine proteases that both engage a receptor called PAR2 and cleave pro-matrix metalloproteinase-9 into its active form. Active matrix metalloproteinase-9 degrades basement membrane and extracellular matrix — the physical scaffolding that keeps cells in their proper tissue — enabling cancer cells to migrate, invade lymphatic and blood vessels, and spread. P. gingivalis also induces immune-checkpoint molecules B7-H1 and B7-DC on oral squamous cell carcinoma cells, which are associated with promoting regulatory T cells that suppress effective anti-tumor immunity. F. nucleatum uses partly overlapping, partly distinct tactics. It is strongly proinflammatory — a positive correlation between local cytokine levels and Fusobacterium species has been shown in colorectal cancer cases. In a mouse model of intestinal tumorigenesis, F. nucleatum recruits tumor-infiltrating immune cells and generates a proinflammatory microenvironment that promotes cancer progression. It activates p38 signaling, which drives secretion of matrix metalloproteinase-9 and matrix metalloproteinase-13, further facilitating invasion. Its most direct oncogenic interaction involves an adhesin called FadA, which binds to E-cadherin on colon cancer cells and activates beta-catenin signaling — a pathway that increases activity of oncogenes, Wnt targets, and proinflammatory cytokines while stimulating cancer cell proliferation. The evidence for this is quantitative: fadA gene levels in colon tissue from colorectal cancer patients were more than ten times higher compared with normal individuals. That is not a subtle difference. Taken together, the two organisms cover a remarkable range of pro-tumorigenic functions — inhibiting apoptosis, accelerating cell-cycle progression, degrading extracellular matrix, suppressing anti-tumor immune responses, and generating chronic inflammation. Whitmore and Lamont describe this as a plausible mechanistic basis for cancer promotion, distinct from the alternative explanation that tumors simply create favorable environments for bacterial colonization. Which brings the review to its honest close. These bacteria are common. Most people have them. Cancer develops in only some. Why? Whitmore and Lamont point to three factors: the constraining influence of other bacteria in the oral community, the multifactorial nature of cancer itself — where oral bacteria may play a contributory but not exclusive role alongside age, genetics, tobacco, and viral infections — and host immune status, which determines whether these organisms can establish the persistent, immune-disrupting infections that seem to matter most. They also acknowledge that causality could run in both directions: precancerous lesions might favor bacterial colonization, meaning the relationship is not simply bacteria causing cancer but a more entangled progression. The clinical implication, stated cautiously but explicitly, is that detection of P. gingivalis or F. nucleatum in precancerous lesions could serve as a poor prognosis indicator. A two-fold increase in pancreatic cancer risk from serological exposure to P. gingivalis, and more than a tenfold elevation of F. nucleatum's FadA gene levels in colorectal tumors — those are not trivial signals. They suggest that the same organisms we study in the context of gum disease may, in the future, help flag patients on a path toward something far worse. That would be H. pylori's legacy, extended to the community of bacteria living just inside your lips. This lecture was created by ennepō. Go to https://ennepo.ai to Discover, Create and Follow the latest research in your field. Read when you can. Listen when you want to.